Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that affects the microscopic, hair-like structures known as motile cilia. These tiny cellular structures act like biological motors and are found in the respiratory tract, reproductive system, and fluid-filled spaces of the brain.

When genetic mutations disrupt the instructions needed to build or control these structures, the cilia may be

Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that affects the tiny hair-like structures responsible for moving mucus through the respiratory tract. When these cilia don't function properly, mucus can remain trapped in the lungs, contributing to chronic infections, inflammation, and long-term airway damage such as bronchiectasis.

Because the body's natural mucus-clearance system is impaired, airway clearance is a central part of daily PCD management. A variety of breathing techniques, physical therapies, and medical devices can help people move mucus out of their lungs.

However, airway-clearance therapy isn't

For decades, the clinical understanding of Primary Ciliary Dyskinesia (PCD) was relatively straightforward: PCD causes defective mucociliary clearance because the airway cilia do not beat normally, but the body's cough reflex remains intact and provides an important backup mechanism for moving mucus out of the lungs.

Because cough can help compensate for impaired mucociliary transport, airway-clearance therapies for PCD have traditionally focused on mobilizing mucus so that the person can cough it out. Current clinical guidance continues to emphasize cough as an important component of airway clearance. 

But there is a more complicated question emerging:

When people think about inflammation in Primary Ciliary Dyskinesia (PCD), they may picture an infection or a pulmonary flare—something that happens when a person is obviously sick.

But PCD can be more complicated than that.

Because the underlying problem with mucociliary clearance is always present, the airways can remain